Edwards Lifesciences 

€59.11
215
-€1.64-2.7% 今天

統計

當日最高
59.11
當日最低
59.11
52週最高
-
52週最低
-
成交量
0
平均成交量
-
市值
42.14B
市盈率
27.54
股息收益率
-
股息
-

即將到來

收益

23Oct預期
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
下一個
0.55
0.58
0.61
0.65
預期每股收益
0.6141651331600001
實際每股收益
N/A

人們還關注

此列表基於在 Stock Events 上關注 EWL.F 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

分析師評級

82.32平均價格目標
最高估價為 €105。
來自過去 6 個月內的 21 個評級。這不是投資建議。
買入
48%
持有
52%
賣出
0%

關於

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Show more...
首席執行官
Mr. Bernard J. Zovighian
員工
19800
國家
US
ISIN
US28176E1082
WKN
000936853

上市公司